Melphalan
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Melphalan: From Alkylating Agent Chemotherapy to Gonadal Germ Cell Tumor
One-Sentence Summary
Melphalan is a classic alkylating agent used in cytotoxic chemotherapy; no original approved-indication or market license record is available for this jurisdiction in the current evidence pack. The TxGNN model predicts it may be effective for Gonadal Germ Cell Tumor, with 8 clinical trials and 4 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file — no approved indication text or license record available (drug not marketed in this jurisdiction) |
| Predicted New Indication | Gonadal Germ Cell Tumor |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L2 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on the information available in the evidence pack, Melphalan is an alkylating agent that causes DNA cross-linking and double-strand breaks, giving it potent cytotoxic activity against rapidly proliferating tumor cells. This mechanistic profile is what underlies its use across multiple malignancies as a component of high-dose chemotherapy regimens.
Germ cell tumors — particularly platinum-resistant or relapsed cases — are highly sensitive to alkylating-agent cytotoxicity. High-dose melphalan combined with autologous stem cell rescue is already an established salvage chemotherapy strategy in relapsed/refractory germ cell tumors, which gives this prediction a mechanistic and practical foundation beyond a pure model score.
This is corroborated by a directly relevant Phase 2 trial (NCT00936936, n=64) that specifically enrolled patients with poor-prognosis relapsed germ-cell tumors and used melphalan as part of a high-dose combination regimen, together with decades of literature on melphalan-based (“sarcolysin”) chemotherapy for testicular seminoma dating back to the 1950s–1970s.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00936936 | Phase 2 | Completed | 64 | High-dose chemotherapy (gemcitabine/docetaxel/melphalan/carboplatin, then ifosfamide/carboplatin/etoposide) for poor-prognosis relapsed germ-cell tumors — direct, disease-specific evidence |
| NCT00003425 | Phase 1/2 | Completed | 25 | Escalating-dose melphalan with autologous stem cell support and amifostine cytoprotection; general solid-tumor population, may include germ cell tumor patients |
| NCT00060255 | Phase 2 | Completed | 451 | Platform trial comparing 8 high-dose chemo regimens ± TBI before autologous transplant for hematologic malignancies/selected solid tumors |
| NCT00536601 | N/A | Completed | 174 | Pilot trial of high-dose chemo regimens ± TBI before autologous stem cell transplant; not disease-specific |
| NCT01272817 | N/A | Completed | 36 | Nonmyeloablative allogeneic HSCT platform trial (melphalan + cladribine arm); not disease-specific |
| NCT00638898 | Phase 1 | Completed | 25 | Busulfan/melphalan/topotecan high-dose regimen before autologous HSCT in advanced/recurrent tumors; not disease-specific |
| NCT00003926 | Phase 1 | Terminated | 13 | Amifostine chemoprotection with autologous stem cell transplant for pediatric solid/brain tumors; melphalan is background regimen only |
| NCT00002750 | Phase 1 | Completed | 6 | Intrathecal melphalan for recurrent neoplastic meningitis; different route/indication, indirect reference only |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 4270380 | 1973 | Review | Oncology | Review of chemotherapy approaches for testicular germinal tumors, including alkylating agents |
| 24913 | 1977 | Review | The Urologic Clinics of North America | Review of seminoma management, including chemotherapy options |
| 13392619 | 1956 | Case report | Voprosy Onkologii | Early clinical experience treating testicular seminoma and its metastases with sarcolysin (an early melphalan-related alkylating agent) |
| 14151951 | 1964 | Basic research | Acta – Unio Internationalis Contra Cancrum | Studies pituitary follicle-stimulating function; low direct relevance to germ cell tumor treatment, included for completeness only |
EU Market Information
Melphalan currently has no marketing authorization on file in this jurisdiction (Market Status: Not Marketed; Total Authorizations: 0). No license or product-level data is available to summarize.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (Alkylating agent, nitrogen mustard derivative) |
| Myelosuppression Risk | High — evidence base consistently uses melphalan only at high doses with autologous stem cell rescue, indicating dose-limiting bone marrow toxicity |
| Emetogenicity Classification | Moderate to High (dose-dependent; high-dose IV regimens seen in the evidence are highly emetogenic) |
| Monitoring Items | CBC with differential, renal function, hepatic function, mucositis assessment |
| Handling Protection | Requires cytotoxic/hazardous drug handling precautions (PPE, closed-system transfer where applicable) |
Detailed formal toxicity data was not available in this evidence pack; please refer to the SmPC for authoritative dosing and toxicity information.
Safety Considerations
Please refer to the SmPC for safety information. Key warnings, contraindications, and drug interaction data are currently marked as data gaps and could not be evaluated (this is a Blocking gap per the evidence pack — see Conclusion below).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A direct, disease-specific Phase 2 trial (NCT00936936) and decades of literature support melphalan’s mechanistic and practical rationale for relapsed/refractory germ cell tumors, but the safety picture cannot yet be evaluated because TFDA-equivalent label warnings/contraindications are missing — this is flagged as a Blocking data gap that must be resolved before advancing to a formal safety assessment (S1).
To proceed, the following is needed:
- TFDA/regulatory label warnings and contraindications (Blocking gap, DG001) — required before S1 safety evaluation
- Detailed mechanism of action data from DrugBank (High-severity gap, DG002)
- Confirmation of original approved indication and route compatibility (currently absent from regulatory records)
- Drug-drug interaction data (currently “not_found”)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.